# TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

> **NCT05901428** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 1736 (estimated)

## Conditions studied

- Hormone Receptor Positive HER-2 Negative Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05901428
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2026-06
- **Final completion:** 2028-06
- **Target enrollment:** 1736 (ESTIMATED)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05901428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05901428, "TCb vs EC-T in High Risk ER+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05901428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*